TROP-2 — Targeted Therapies, Trials & Pipeline
A broadly expressed epithelial antigen targeted by ADCs in breast, lung and urothelial cancers.
Approved drugs targeting TROP-2
datopotamab deruxtecan-dlnk
·
Sacituzumab govitecan
Investigational pipeline agents
AZD5335
·
Sacituzumab tirumotecan